Business
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research.[1] A single-dose of its immunocontraceptive vaccine SpayVac™ vaccine ("SpayVac") significantly reduced fertility to 11% in vaccinated deer compared to a fertility rate of 86% in contro
About this update from Biovaxys Technology Corp
[{"type":"text","content":"VANCOUVER, BC and MADISON, Wis., Oct. 14, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to announce that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research.[1] A single-dose of its immunocontraceptive vaccine SpayVac™ vaccine ("SpayVac") significantly reduced fertility to 11% in vaccinated deer compared to a fertility rate of 86% in control animals. At the core of SpayVac is a patented technology for a liposome-based delivery platform designed to create long-lasting, targeted immune responses that is licensed from BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB). The liposomes are composed of naturally occurring phospholipids. These liposomes encapsulate the antigen and improve the immune system's response to vaccination.","length":987,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"BioVaxys Technology Corp. (PRNewsfoto/BioVaxys Technology Corp.)","displaySize":"","headline":null,"caption":"BioVaxys Technology Corp. (PRNewsfoto/BioVaxys Technology Corp.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":63,"url":"https://media.zenfs.com/en/prnewswire.com/cca0b1a397afc4499b82a11ef5413aff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vz89JzLyu28IxHOM1sp31Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cca0b1a397afc4499b82a11ef5413aff","width":400,"height":63}},"href":"https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"The one-year study was done with 47 free-ranging red deer (Cervus elaphus) and used camera traps, GPS collars, and fecal progesterone metabolites to intensively monitor pregnancies. The contraceptive efficacy of SpayVac has now been clinically validated in three distinct deer species: fallow deer (Dama dama), white-tailed deer (Odocoileus virginianus), and red deer. These results indicate a broad potential for SpayVac to be successfully applied across a wide range of deer populations.","length":48...